Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar;26(Suppl 1):5-9.
doi: 10.1007/s00520-018-4131-3. Epub 2018 Mar 19.

CINV: still troubling patients after all these years

Matti Aapro  1
Affiliations

CINV: still troubling patients after all these years

Matti Aapro. Support Care Cancer. 2018 Mar.

Abstract

Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared side effects experienced by patients with cancer. The precise physiologic mechanisms responsible for acute and delayed CINV continue to be elucidated and have provided an opportunity to develop antiemetic therapies targeting these pathways. The emergence of receptor antagonists targeting serotonin and neurokinin-1 have revolutionized the prevention of CINV, significantly reducing the impact of this side effect and improving patient quality of life. However, several areas of unmet need remain, including adequate prevention of nausea, rather than just vomiting, in patients receiving chemotherapy for cancer. Prevention of delayed CINV and anticipatory CINV, as well as management of breakthrough CINV, also continues to challenge patients and clinicians. Ongoing research continues to address these areas to improve antiemetic therapies and guidelines.

Keywords: 5-HT3 receptor antagonist; Anticipatory CINV; Breakthrough CINV; CINV; Chemotherapy-induced nausea and vomiting; NK-1 receptor antagonist.

PubMed Disclaimer

Conflict of interest statement

Dr. Aapro has disclosed that he has received consulting fees or honoraria from Amgen. He has also received payment for lectures and/or support for travel fromAmgen, Helsinn, Hospira, Johnson & Johnson, Novartis, Pierre Fabre Medicament, Roche, Sandoz, TESARO, Teva, and Vifor Pharma. Dr. Aapro has received research funding from Helsinn, Hospira, Novartis, Pierre Fabre Medicament, and Sandoz. He has also disclosed receiving fees for participation in advisoryor review activities from Helsinn Healthcare, Hospira, Merck, Merck KGaA, Pierre Fabre Medicament, Sandoz, TESARO, Teva, and ViforPharma.

Figures

Fig. 1
Fig. 1
Pathophysiology of chemotherapy-induced nausea and vomiting1. From N Engl J Med, Navari RM, Aapro M, Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting, Volume No. 374, Page No. 1357, Copyright © 2016 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society
See this image and copyright information in PMC

References

    1. Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;374:1356–1367. doi: 10.1056/NEJMra1515442. - DOI - PubMed
    1. Bayo J, Fonseca PJ, Hernando S, Servitja S, Calvo A, Falagan S, García E, González I, de Miguel MJ, Pérez Q, Milena A, Ruiz A, Barnadas A. Chemotherapy-induced nausea and vomiting: pathophysiology and therapeutic principles. Clin Transl Oncol. 2012;14:413–422. doi: 10.1007/s12094-012-0818-y. - DOI - PubMed
    1. Higgins GA, Kilpatrick GH, Bunce KT, et al. 5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br J Pharmacol. 1989;97:247–235. doi: 10.1111/j.1476-5381.1989.tb11948.x. - DOI - PMC - PubMed
    1. Janelsins MC, Tejani M, Kamen C, et al (2013) Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother 14:757–766 - PMC - PubMed
    1. Rojas C, Raje M, Tsukamoto T, Slusher BS. Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis. Eur J Pharmacol. 2014;722:26–37. doi: 10.1016/j.ejphar.2013.08.049. - DOI - PubMed

Publication types

LinkOut - more resources